Literature DB >> 1419025

Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts.

A J Peacock1, K E Dawes, A Shock, A J Gray, J T Reeves, G J Laurent.   

Abstract

The remodeling of pulmonary vessels that occurs in association with pulmonary hypertension involves, in part, thickening of the adventitia. The stimulus for this process is not understood. One explanation is that endothelial cells secrete a growth factor that expands the local population of fibroblasts by acting as a chemoattractant and mitogen. Endothelins are a family of potent newly discovered vasoactive peptides. One of these compounds, endothelin-1 (ET-1), is secreted by endothelial cells and is known to constrict pulmonary vessels. Another, endothelin-3 (ET-3), is not secreted by endothelial cells and is less potent as a pulmonary vasoconstrictor. We hypothesized that the endothelins may have the capacity both to constrict these vessels and to initiate fibroblast chemotaxis and replication. Here we investigated the effects of both ET-1 and ET-3 on the chemotaxis and replication of fibroblasts derived from pulmonary vessels. Cells were isolated from rat pulmonary arteries, cultured in medium and 10% newborn calf serum, and used between passages 2 and 5. Chemotaxis was assessed using a modified Boyden chamber with a polycarbonate filter (pore size, 8 microns) separating cells in the upper chambers from endothelin in the lower chambers. Replication was assessed both by direct cell counts and by a colorimetric assay based on uptake and subsequent release of methylene blue. Both ET-1 and ET-3 induced chemotaxis of pulmonary artery fibroblasts and did so in a dose-dependent fashion. The maxima for both peptides occurred at a concentration of about 10(-7) M, when chemotaxis was greatest for ET-1 (22 +/- 1.4 versus 14 +/- 1.8 cells/grid [mean +/- SEM], (P < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1419025     DOI: 10.1165/ajrcmb/7.5.492

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  23 in total

Review 1.  Cellular responses to hypoxia in the pulmonary circulation.

Authors:  S O Brij; A J Peacock
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

2.  Endothelin-1-induced endothelial microvesicles impair endothelial cell function.

Authors:  L Madden Brewster; Vinicius P Garcia; Ma'ayan V Levy; Kelly A Stockelman; Anabel Goulding; Noah M DeSouza; Jared J Greiner; Jamie G Hijmans; Christopher A DeSouza
Journal:  J Appl Physiol (1985)       Date:  2020-04-23

3.  NFATc3 contributes to intermittent hypoxia-induced arterial remodeling in mice.

Authors:  Sergio de Frutos; Elizabeth Caldwell; Carlos H Nitta; Nancy L Kanagy; Jian Wang; Wei Wang; Mary K Walker; Laura V Gonzalez Bosc
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-05-21       Impact factor: 4.733

4.  EndothelinB receptor-mediated contraction in human pulmonary resistance arteries.

Authors:  K M McCulloch; C C Docherty; I Morecroft; M R MacLean
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

Review 5.  The mesothelial cell and its role in asbestos-induced pleural injury.

Authors:  M Kuwahara; E Kagan
Journal:  Int J Exp Pathol       Date:  1995-06       Impact factor: 1.925

Review 6.  Pulmonary arterial hypertension: a comparison between children and adults.

Authors:  R J Barst; S I Ertel; M Beghetti; D D Ivy
Journal:  Eur Respir J       Date:  2011-03       Impact factor: 16.671

Review 7.  The Nax (SCN7A) channel: an atypical regulator of tissue homeostasis and disease.

Authors:  David Dolivo; Adrian Rodrigues; Lauren Sun; Yingxing Li; Chun Hou; Robert Galiano; Seok Jong Hong; Thomas Mustoe
Journal:  Cell Mol Life Sci       Date:  2021-06-08       Impact factor: 9.261

8.  Atherosclerosis in sickle cell disease - a review.

Authors:  Mohamed A Elsharawy; Khaled M Moghazy; Mohamed A Shawarby
Journal:  Int J Angiol       Date:  2009

Review 9.  The role of endothelin-1 in the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Jeffrey J Swigris; Kevin K Brown
Journal:  BioDrugs       Date:  2010-02-01       Impact factor: 5.807

10.  A review of current and novel therapies for idiopathic pulmonary fibrosis.

Authors:  Rokhsara Rafii; Maya M Juarez; Timothy E Albertson; Andrew L Chan
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.